AddLife AB (publ) (ALIF-B.ST)
SEK 137.2
(2.39%)
SEK 137.2
(2.39%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 5.01 Billion SEK | -3.8% |
| 2022 | 5.21 Billion SEK | 38.81% |
| 2021 | 3.75 Billion SEK | 536.96% |
| 2020 | 589.8 Million SEK | -26.02% |
| 2019 | 797.2 Million SEK | 1.55% |
| 2018 | 785 Million SEK | 50.47% |
| 2017 | 521.7 Million SEK | 70.43% |
| 2016 | 306.1 Million SEK | -35.5% |
| 2015 | 474.6 Million SEK | 972.43% |
| 2014 | -54.4 Million SEK | -21.7% |
| 2013 | -44.7 Million SEK | 45.88% |
| 2012 | -82.6 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 4.59 Billion SEK | -12.67% |
| 2024 Q3 | 5.17 Billion SEK | 12.68% |
| 2024 Q1 | 5.25 Billion SEK | 4.78% |
| 2023 Q2 | 5.63 Billion SEK | 8.4% |
| 2023 Q3 | 5.42 Billion SEK | -3.8% |
| 2023 FY | 5.01 Billion SEK | -3.8% |
| 2023 Q4 | 5.01 Billion SEK | -7.49% |
| 2023 Q1 | 5.2 Billion SEK | -0.29% |
| 2022 Q3 | 5.38 Billion SEK | 0.56% |
| 2022 Q2 | 5.35 Billion SEK | 12.21% |
| 2022 FY | 5.21 Billion SEK | 38.81% |
| 2022 Q1 | 4.77 Billion SEK | 27.13% |
| 2022 Q4 | 5.21 Billion SEK | -3.23% |
| 2021 Q3 | 1.94 Billion SEK | -50.27% |
| 2021 Q1 | 436 Million SEK | -26.08% |
| 2021 Q2 | 3.9 Billion SEK | 795.64% |
| 2021 FY | 3.75 Billion SEK | 536.96% |
| 2021 Q4 | 3.75 Billion SEK | 93.45% |
| 2020 Q2 | 857 Million SEK | -13.7% |
| 2020 FY | 589.8 Million SEK | -26.02% |
| 2020 Q4 | 589.8 Million SEK | -16.69% |
| 2020 Q3 | 708 Million SEK | -17.39% |
| 2020 Q1 | 993 Million SEK | 24.56% |
| 2019 Q3 | 868 Million SEK | 16.35% |
| 2019 Q4 | 797.2 Million SEK | -8.16% |
| 2019 FY | 797.2 Million SEK | 1.55% |
| 2019 Q1 | 530 Million SEK | -32.48% |
| 2019 Q2 | 746 Million SEK | 40.75% |
| 2018 Q1 | 495 Million SEK | -5.12% |
| 2018 Q3 | 610 Million SEK | 15.53% |
| 2018 FY | 785 Million SEK | 50.47% |
| 2018 Q4 | 785 Million SEK | 28.69% |
| 2018 Q2 | 528 Million SEK | 6.67% |
| 2017 Q2 | 545 Million SEK | 1.49% |
| 2017 Q1 | 537 Million SEK | 75.43% |
| 2017 FY | 521.7 Million SEK | 70.43% |
| 2017 Q4 | 521.7 Million SEK | -13.91% |
| 2017 Q3 | 606 Million SEK | 11.19% |
| 2016 Q4 | 306.1 Million SEK | -43.34% |
| 2016 Q3 | 540.2 Million SEK | -0.94% |
| 2016 Q1 | 474.6 Million SEK | -45.2% |
| 2016 Q2 | 545.3 Million SEK | 14.9% |
| 2016 FY | 306.1 Million SEK | -35.5% |
| 2015 Q4 | 866.1 Million SEK | 0.0% |
| 2015 FY | 474.6 Million SEK | 972.43% |
| 2015 Q1 | -54.4 Million SEK | 0.0% |
| 2014 FY | -54.4 Million SEK | -21.7% |
| 2013 FY | -44.7 Million SEK | 45.88% |
| 2012 FY | -82.6 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Biotage AB (publ) | -444 Million SEK | 1229.955% |
| Bonesupport Holding AB (publ) | -149.86 Million SEK | 3447.635% |
| Doxa AB (publ) | -102.2 Million SEK | 5009.002% |
| Elekta AB (publ) | 4.46 Billion SEK | -12.262% |
| iZafe Group AB (publ) | -2.65 Million SEK | 188779.955% |
| Ortivus AB (publ) | 4.19 Million SEK | -119580.344% |
| Ortivus AB (publ) | 4.19 Million SEK | -119580.344% |
| Q-linea AB (publ) | -61.33 Million SEK | 8280.336% |
| S2Medical AB (publ) | -1.51 Million SEK | 330812.419% |
| Synsam AB (publ) | 2.67 Billion SEK | -87.692% |